OR WAIT 15 SECS
The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.
On Nov. 14, 2017, Pall Corporation, a provider of filtration, separation, and purification technologies, debuted the new Cadence Inline Diafiltration (ILDF) modules for scalable single-pass diafiltration (DF) in continuous bioprocessing. The new modules provide repeated downstream dilution and concentration cycles without a recirculation loop. They were exclusively showcased during Pall's Leadership Forum series hosted in the company’s Westborough, MA, center of excellence on Nov. 14–15, 2017.
The modules enable fully continuous DF processes in ultrafiltration and DF (UF/DF) processing steps. They are in a range of size formats that can accommodate various processing volumes. They are also portable, making them capable of continuous monoclonal antibody downstream purification processing in one or more locations.
"Single-pass tangential flow filtration, or SPTFF, revolutionized how TFF is implemented in biotech, vaccine, blood plasma, and other applications, yet challenges remained," said Mario Philips, vice president and general manager of Pall Life Sciences, in a company press release. "The Cadence ILDF device eliminates those challenges, making continuous processing of the final UF/DF of drug substance possible, and takes another step forward in Pall delivering the only viable end-to-end integrated continuous bioprocessing platform on the market. We are excited to preview the technology to key customers and business colleagues this week in Westborough."
The company’s standard T-Series cassettes act as the building blocks for the new Cadence ILDF module, which is offered with either Delta regenerated cellulose or Omega polyethersulfone membranes. These provide high flux, high selectivity, and low protein binding characteristics. The removal factor of the module is in the order of ≥ 3-log in a scalable, accurate platform with proven selectivity and low protein binding attributes, according to the company. The new modules enable significantly reduced system hold-up volume and feature a user-friendly, holderless design.
Source: Pall Corporation
Related Content:Manufacturing, Monoclonal Antibodies | Process Control, Automation, and PAT | Manufacturing | News | Downstream Processing | Manufacturing Systems, Single-Use | Upstream Processing | Supplier News | Manufacturing Equipment, Biologics | Manufacturing, Recombinant Proteins | Manufacturing, Biologics | Manufacturing, Separation and Purification | Manufacturing, Parenterals and Injectables | Manufacturing Equipment, Downstream Processing | Manufacturing Equipment, Upstream Processing | Manufacturing, Continuous Biologics Processing